About Us

Rose Pharma is a clinical phase biopharmaceutical company focusing on development of novel treatments for irritable bowel syndrome (IBS) and functional dyspepsia (FD), disorders which affect 10-20% of the general population and which are large unmet clinical needs. The platform technology is based around glucagon-like peptide-1 (GLP-1), and the lead molecule is
ROSE-010, a stable GLP-1 analogue.

Rose Pharma was formerly known as Gastrotech Pharma.
Gastrotech was founded in 2003 and had a broad interest in gastroenterology.

With the positive clinical data on IBS and GLP-1, we are now focused on development of ROSE-010. To reflect this and to underline the company’s tight therapeutic focus, we have renamed the company
Rose Pharma.